What is Chardan Capital’s Estimate for ANRO FY2025 Earnings?

Alto Neuroscience, Inc. (NYSE:ANRO) – Stock analysts at Chardan Capital issued their FY2025 EPS estimates for Alto Neuroscience in a research note issued to investors on Wednesday, November 19th. Chardan Capital analyst K. Nakae anticipates that the company will post earnings of ($2.45) per share for the year. Chardan Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.54) per share. Chardan Capital also issued estimates for Alto Neuroscience’s FY2026 earnings at ($1.80) EPS.

Several other brokerages have also issued reports on ANRO. Wall Street Zen upgraded Alto Neuroscience from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. BTIG Research began coverage on Alto Neuroscience in a research report on Monday, November 17th. They set a “buy” rating and a $27.00 price objective on the stock. Jefferies Financial Group upped their target price on Alto Neuroscience from $15.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, November 12th. HC Wainwright lifted their price target on shares of Alto Neuroscience from $10.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, October 24th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Alto Neuroscience in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $23.83.

Alto Neuroscience Stock Down 5.3%

Shares of ANRO opened at $13.40 on Monday. The company has a 50-day simple moving average of $8.77 and a 200-day simple moving average of $4.97. The firm has a market capitalization of $416.34 million, a P/E ratio of -5.85 and a beta of 2.81. The company has a debt-to-equity ratio of 0.20, a quick ratio of 15.42 and a current ratio of 15.42. Alto Neuroscience has a 52 week low of $1.60 and a 52 week high of $16.49.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.14.

Institutional Trading of Alto Neuroscience

Several institutional investors have recently bought and sold shares of ANRO. Bank of Montreal Can acquired a new position in Alto Neuroscience during the second quarter worth $25,000. Ground Swell Capital LLC bought a new stake in shares of Alto Neuroscience in the 2nd quarter worth about $27,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Alto Neuroscience in the 2nd quarter worth about $33,000. AlphaCore Capital LLC increased its position in shares of Alto Neuroscience by 100.0% during the 2nd quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $44,000 after purchasing an additional 10,000 shares in the last quarter. Finally, AQR Capital Management LLC bought a new position in Alto Neuroscience during the 1st quarter valued at about $52,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.